SCHEMBL13635623

SCHEMBL13635623

CNC(=O)CCCCCCC(=O)OC(C)C

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.63
EPHX2 P34913 1/20 0.44
MAPT P10636 3/20 0.42
MAPK1 P28482 2/20 0.42
ALDH1A1 P00352 2/20 0.41
GAA P10253 2/20 0.41
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
FAAH O00519 1/20 0.40
RECQL P46063 1/20 0.38
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HDAC5 Q9UQL6 1/20 0.37
TSHR P16473 1/20 0.37
PRKCA P17252 1/20 0.37
PRKCE Q02156 1/20 0.37
PRKCQ Q04759 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13361470 0.86 LMNA (0.66) LMNAMAPTMAPK1ALDH1A1KMT2A
SCHEMBL878351 0.86 MAPT (0.51) LMNAEPHX2MAPTTSHR
SCHEMBL494007 0.85 LMNA (0.83) LMNAEPHX2MAPTMAPK1ALDH1A1
SCHEMBL10788600 0.85 LMNA (0.83) LMNAEPHX2MAPTMAPK1ALDH1A1
SCHEMBL495551 0.85 LMNA (0.83) LMNAEPHX2MAPTMAPK1ALDH1A1
SCHEMBL494127 0.85 LMNA (0.83) LMNAEPHX2MAPTMAPK1ALDH1A1
SCHEMBL495594 0.85 LMNA (0.83) LMNAEPHX2MAPTMAPK1ALDH1A1
SCHEMBL494255 0.85 LMNA (0.83) LMNAEPHX2MAPTMAPK1ALDH1A1
SCHEMBL9216453 0.85 LMNA (0.83) LMNAEPHX2MAPTMAPK1ALDH1A1
SCHEMBL12132118 0.85 LMNA (0.83) LMNAEPHX2MAPTMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999289-B2 Treatment of protein degradation disorders PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2015-04-07 US disclosed
US-8304451-B2 Histone deacetylase and tubulin deacetylase inhibitors PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-11-06 US disclosed
US-20090209590-A1 Histone Deacetylase and Tubulin Deacetylase Inhibitors PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2009-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209590-A1 Histone Deacetylase and Tubulin Deacetylase Inhibitors HDAC6, HDAC1, HDAC5 LMNA 2250/4885EPHX2 4113/4885MAPT 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.